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Abstract
Background: Accurate parasitological diagnosis of malaria is essential for targeting treatment where more than
one species coexist. In this study, three rapid diagnostic tests (RDTs) (AccessBio CareStart (CSPfPan), CareStart PfPv
(CSPfPv) and Standard Diagnostics Bioline (SDBPfPv)) were evaluated for their ability to detect natural Plasmodium
vivax infections in a basic clinic setting. The potential for locally made evaporative cooling boxes (ECB) to protect
the tests from heat damage in high summer temperatures was also investigated.
Methods: Venous blood was drawn from P. vivax positive patients in Jalalabad, Afghanistan and tested against a
panel of six RDTs. The panel comprised two of each test type; one group was stored at room temperature and the
other in an ECB. RDT results were evaluated against a consensus gold standard based on two double-read
reference slides and PCR. The sensitivity, specificity and a measure of global performance for each test were
determined and stratified by parasitaemia level and storage condition.
Results: In total, 306 patients were recruited, of which 284 were positive for P. vivax, one for Plasmodium malariae
and none for Plasmodium falciparum; 21 were negative. All three RDTs were specific for malaria. The sensitivity and
global performance index for each test were as follows: CSPfPan [98.6%, 95.1%], CSPfPv [91.9%, 90.5%] and SDBPfPv
[96.5%, 82.9%], respectively. CSPfPv was 16% less sensitive to a parasitaemia below 5,000/μL. Room temperature
storage of SDBPfPv led to a high proportion of invalid results (17%), which reduced to 10% in the ECB. Throughout
the testing period, the ECB maintained ~8°C reduction over ambient temperatures and never exceeded 30°C.
Conclusions: Of the three RDTs, the CSPfPan test was the most consistent and reliable, rendering it appropriate for
this P. vivax predominant region. The CSPfPv test proved unsuitable owing to its reduced sensitivity at a
parasitaemia below 5,000/μL (affecting 43% of study samples). Although the SDBPfPv device was more sensitive
than the CSPfPv test, its invalid rate was unacceptably high. ECB storage reduced the proportion of invalid results
for the SDBPfPv test, but surprisingly had no impact on RDT sensitivity at low parasitaemia.
Background
Over the last 15 years there has been a proliferation of
malaria rapid diagnostic tests (RDT), which vary consid-
erably in format, species detected and performance. As
an aid to diagnosis in resource poor settings, malaria
RDTs are increasingly being incorporated into national
malaria management guidelines [1]. Diagnosis of malaria
by clinical signs and symptoms alone is notoriously
inaccurate; and where incidence is low or falling this
results in high levels of over diagnosis and anti-malarial
overtreatment in patients who do not have parasites and
inadequate treatment in patients who do [2]. This has
been extensively shown in sub-Saharan Africa including
regions of holo and hyper-endemicity [3-7]. In South and
Central Asia, which is predominantly a moderate to low
transmission setting and where the majority of malaria is
the product of two species (Plasmodium falciparum and
Plasmodium vivax), the proportion of patients incorrectly
treated with an anti-malarial is likely to be high where
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laboratory diagnosis is available [8,9] and even higher
where it is not [9]. The WHO Global Malaria Treatment
Guidelines now recommend that all patients are treated
on the basis of a laboratory-confirmed diagnosis [1].
RDT field trials undertaken in falciparum-predominant
countries revealed five key operational issues with RDTs:
(1) variation in quality between different manufacturers
[10]; (2) variation in quality from the same brand but
between lots [11]; (3) compromised performance of
RDTs in field conditions due to heat and humidity expo-
sure [12,13]; (4) geographic variation in RDT parasite
capture rate due to local variations in malaria target anti-
gens [14] and (5) reduced RDT sensitivity in patients
with low parasitaemia [15,16]. The first two issues are
related to manufacturing quality and are being addressed
with the WHO/FIND malaria RDT evaluation pro-
gramme [17,18]; RDTs entering the programme are
required to have reached ISO manufacturing standards
and are tested under standardized conditions by FIND
with banked and cultured samples. The programme is
currently falciparum oriented because non-falciparum
parasites are difficult to culture in vitro and at a global
level, falciparum malaria constitutes the greater threat to
patient morbidity and mortality.
Identifying species is important; in most areas of co-
endemic malaria, P. falciparum is resistant to chloroquine,
which is still widely used to treat P. vivax. Mistreatment of
P. falciparum with chloroquine virtually assures treatment
failure, while treatment of P. vivax with more expensive
artimesinin combination therapy (ACT) is effective [19],
but wastes resources. Treating all undifferentiated fever as
malaria (based on clinical signs) will lead to substantial
wastage of drugs and misses potentially important non-
malarial causes of fever, for example invasive bacterial
infections [20]. Combination RDTs that can distinguish
between P. falciparum and other species are increasingly
favoured by national programmes in this region, princi-
pally because this distinction permits the restriction of
expensive ACT to falciparum malaria alone, reduces the
chance of treatment failure and improves treatment of
non-malarial causes of fever. Other advantages include
cost-effectiveness and improved ability to monitor disease
trends. There is also increasing recognition of the capacity
for P. vivax malaria to become clinically severe[21-23].
With over 70% of world’s population in malaria endemic
regions being at risk of P. vivax, this problem is far from
trivial [24,25]. The ideal would be the universal deploy-
ment of effective point of care tests [1] that can rapidly
identify all human malaria species and effectively target
treatment for malaria and non-malarial causes of fever.
This study was conducted in Afghanistan, where malaria
is predominantly caused by P. vivax, with P. falciparum a
minority cause of disease. The country is hypo-endemic,
with transmission varying widely by geographical area and
season [26]. Most febrile illness is not caused by malaria,
and most malaria is not caused by P. falciparum [27].
Within the Afghan healthcare system, malaria is currently
diagnosed either by microscopy, or by clinical symptoms
and signs alone. Currently 40% of Afghanistan’s Basic
Health Centres (BHCs) lack laboratories capable of per-
forming malaria microscopy. This presents difficulties in
meeting the requirements of revised WHO Malaria Treat-
ment Guidelines. In the health facilities that currently lack
a microscopy laboratory, RDTs may be the appropriate
alternative.
Despite the importance of the disease, relatively few stu-
dies have specifically examined the ability of RDTs to
detect vivax malaria. Studies that have been undertaken in
the field indicate that the sensitivity of a number of vivax-
detecting RDTs is greatly reduced at low parasitaemia
[15,28,29]. Laboratory-based analyses also demonstrate
that Plasmodium lactate dehydrogenase (pLDH) detecting
antibodies are particularly vulnerable to heat degradation
above 30°C [12,13]. Although only a proxy for variable-
temperature field conditions, heat stability testing has thus
far been typically conducted at FIND-certified reference
laboratories, using incubators pre-set to four fixed tem-
peratures. RDTs that have been stored in incubators
between temperatures of 35 and 60°C for one month or
more have shown either consistent performance through-
out or reduced sensitivity to low parasitaemia after storage
at the higher temperature (see [15,30] for example). It is,
therefore, likely that pLDH sensitivity is causally linked to
both temperature and parasite levels.
The performance and suitability of selected vivax-
detecting RDTs under field conditions was investigated
at the Malaria Reference Centre, Jalalabad, Afghanistan,
with a focus on the practical challenges to vivax-predo-
minant co-endemic regions: the diagnostic implications
of heat-sensitive target antigens, the possibility of miti-
gating any heat damage with an appropriate technology
that does not require electricity, and the impact of para-
sitaemia on the diagnostic accuracy of the tests.
Methods
The principal objective was to evaluate the performance of
three types of malaria RDT capable of detecting both
P. falciparum and P. vivax in a controlled operational set-
ting. The sensitivity, specificity and a measure of global
performance for each RDT were examined across a range
of representative levels of P. vivax parasitaemia found
amongst outpatients. As a secondary aim, an evaporative
cooling device was evaluated for its capacity to maintain
or improve RDT sensitivity to P. vivax when compared to
RDTs stored at ambient Afghan summer temperatures (38
- 45°C). Finally, each RDT was assessed to determine
whether its performance under standard field conditions
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met WHO requirements for use in national programmes
(sensitivity and specificity > 95%).
Patient recruitment
Patients were recruited sequentially over a period of
three months (June to August 2009) from seven outpati-
ent facilities within a 5 km radius of the Malaria Refer-
ence Centre (MRC) in Jalalabad, where the evaluation of
the rapid tests was conducted. The prevalence of vivax
malaria amongst fever patients in the study area during
the recruitment period was approximately 15%. Samples
were kept in a cool box and transported to the MRC
within two hours after collection from the patient. The
panel of rapid tests were then conducted on the samples
within 30 minutes of their arrival at the MRC.
Patients were recruited as “vivax positive” if they had a
P. vivax positive clinic slide, as determined by the micro-
scopists at each of the seven clinics during routine exam-
ination, while malaria negative patients were recruited on
the basis of a negative clinic slide. In both cases, recruit-
ment proceeded sequentially until the desired sample
number for each group was reached. Approximately half
of all the malaria cases selected with this protocol were
children less than 10 years of age.
Malaria rapid diagnostic test selection
The types of RDT used in the study were selected accord-
ing to the following criteria of suitability for local and/or
regional deployment: (1) Antigen detecting; (2) Ability to
detect P. falciparum via the P. falciparum-specific HRP2
antigen; (3) Ability to detect P. vivax; (4) Ability to discri-
minate between P. falciparum and P. vivax; (5) Ability to
detect other malaria species, if possible; (6) Easy interpre-
tation of results for both species; (7) Strong performance
under heat stress (exposure to 45°C or higher); (8) Strong
performance in round 1 of the WHO-FIND malaria RDT
product testing programme (if included).
Based on these selection criteria, three tests were cho-
sen for the study: (A) CareStart™ 3-line Pf (HRP2) +
Pan (pLDH) (Product no. G0131, AccessBio, New Jersey,
USA); (B) CareStart™ 3-line Pf (HRP2) + Pv (pv-LDH)
(Product no. G0161, AccessBio, New Jersey, USA); and
(C) Bioline™ 3-line Pf (HRP2) + Pv (pv-LDH) (Product
no. 05FK80, lot no. RDT9004, Standard Diagnostics Inc.,
Kyonggi-do, Korea).
The CareStart PfPan test was included because it scored
highly in the first round of the WHO-FIND evaluations
[17]. The study was conducted prior to the release of the
round 2 evaluation results and the round 1 evaluation did
not include any RDTs with vivax-specific test lines; how-
ever two models were included in this study because of
the potential benefits of having a vivax-specific test line in
a vivax-predominant area. The CareStart PfPv test was
selected to determine if its performance would equal that
of the PfPan RDT made by the same company. The Stan-
dard Diagnostics (Bioline) test was selected because the
model is becoming increasingly easy to access throughout
Asia, but the test had not previously been evaluated in an
operational setting.
The integrity of the tests used in this study was ensured
in the following manner: The temperature during trans-
port was not monitored, but manufacturers were
requested to ship the tests in insulated packaging with ice
packs, in order to mitigate against exposure to high tem-
peratures during transport. A single lot of each test type
was provided specifically for this analysis and the tests
were delivered two months prior to the start of the study,
with an additional 11 months of validity remaining before
they would expire in each case. Transit time for the RDTs
from the manufacturer to the study site was five days for
Standard Diagnostics and three weeks for the AccessBio
tests. All tests were stored in identical conditions in a
cooled warehouse in Nangarhar until one month prior to
the beginning of the study, whereupon half the tests of
each model were transferred to a room temperature cup-
board in the study clinic and the remaining half were
transferred to an evaporative cooling box.
Cooling device selection criteria
Summer temperatures in Afghanistan can rise to over 45°
C, exceeding the maximum storage temperatures for RDTs
recommended by the manufacturers (30°C for AccessBio
CareStart tests and 40°C for Standard Diagnostics Bioline).
As most rural health centres do not have electricity, refri-
gerated storage or air conditioning is not an option. A
locally appropriate cooling technology was therefore used.
The target product profile for this technology was: (1) fea-
sible to manufacture from local materials; (2) simple to
install in clinics; (3) easy to maintain; (4) does not require
electricity; (5) can maintain internal temperature below 30°
C; and (6) remains effective up to an outside ambient tem-
perature of 45°C and 75% relative humidity.
An evaporative cooling box adapted from designs
tested by Bell and others in Cambodia [31] was chosen
for this study (Figure 1). Pre-study enquiries indicated
that health centres would prefer a portable box to
underground pits, since the latter would require quite
significant building work and be potentially disruptive to
the layout of the clinic. Evaporative coolers are appro-
priate technology storage solutions which do not require
electricity or much maintenance to run. The system
consists of an enclosed metal box (the storage space)
with extended sides to form a tray on the top capable of
holding water. The box is covered in hessian, with mate-
rial wicks connecting the hessian cover to the water
filled tray. Water transfers by capillary action via the
wicks to the hessian cover. Water evaporates off the
hessian cover, cooling the metal box and its contents.
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The box was manufactured to the specifications of the
investigators by a local metal worker from aluminium,
with a tailored hessian covering at a cost of USD $70
per unit. Unlike the Cambodian Cooler Box, wicks were
tailored as a continuous extension to the hessian box
covering, since this was found to improve the transfer of
moisture from tray to box covering. Water in the upper
tray was kept topped up to a predetermined mark. The
performance of the prototype unit was evaluated prior
to the start of the study by recording relative humidity
and temperature inside and outside the box on an
hourly basis for eight days. Thereafter, RDTs were
stored in the evaporative cooler box and at room tem-
perature for a minimum of one month prior to patient
recruitment, resulting in a mean storage time in the
study conditions of 2.5 months prior to use. The relative
humidity and temperature within and outside the eva-
porative cooler box continued to be monitored through-
out the study.
Sample size
Sample size was calculated using the package epicalc,
which is a component of the statistical open software, R
[32]. The primary consideration for sample size was that
it should be large enough to include patients with very
low parasitaemia, since this has a known impact on
RDT sensitivity. Parasitaemia less than 500 parasites per
microliter can result in low sensitivity of pLDH based
markers [28]. Recent trials in Afghanistan [33] show
that 6-15% of vivax positive patients harbour < 500
asexual parasites/μL, and around half of patients have a
parasitaemia < 5,000/μl (unpublished obs.).
Where studies have compared RDT accuracy at differ-
ent levels of parasitaemia, the difference in sensitivity
between different types of RDT at similarly low parasi-
taemia can be as little as 1% (SD Bioline vs. Optimal for
Plasmodium vivax parasite densities less than 500/μL,
[28]), 7% (SD Bioline vs. CareStart for Plasmodium falci-
parum [34]), or as much as 20% (Vistapan vs. Paracheck
for P. falciparum parasite densities less than 100/μL
[16]). The potential for each test to equal or exceed 95%
sensitivity (WHO standard) at a typical low parasitaemia
was the main outcome of this study; therefore the study
was powered primarily to detect differences in sensitivity
between low and high parasitaemia and between storage
conditions, but not differences in sensitivity or specifi-
city between tests.
A secondary consideration was the capacity of the
RDTs to detect extremely low levels of parasitaemia in
samples that were slide negative but PCR positive (i.e.
where parasitaemia was below the detection limit of
microscopy). Scant data exist on the proportion of false
negative slides likely to be detected by PCR and it is dif-
ficult to generalize since this proportion depends on
both the PCR method used, the quality of the blood
films and the skill of the microscopist. An additional 20
clinic slide negative patients were recruited to examine
this phenomenon.
To detect 6% hypo-parasitaemic patients (the propor-
tion of the study population with parasitaemia less than
500/μL) with 95% confidence and an alpha of 0.05, a
sample size of 241 P. vivax positive patients was deemed
necessary. This figure was increased to 280 to allow for
exclusion of any records that had missing data. In addi-
tion, a minimum of 20 malaria slide negative patients
would be recruited, resulting in a total target sample
size of 300.
Patient recruitment (inclusion and exclusion criteria)
Patients were recruited over a three month period, from
June to August 2009.
Patients were included if they were over five years, had
given informed consent to participate (or where guar-
dians had given consent in the case of minors) and were
diagnosed by the clinic microscopist as P. vivax positive
(target sample size = 280) or malaria slide negative (tar-
get sample size = 20).
Patients were excluded if they were anaemic (< 7 g/dL
or equivalent clinical evidence), had any blood-based
Figure 1 Evaporative cooler box with drip tray.
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condition which would render blood sample collection
risky, or were suffering from severe malaria as defined
by WHO criteria.
Sample collection and processing
Samples were collected from patients at participating
clinics, as follows. After initial screening by the clinic
microscopist, a further sample of blood was collected via
finger prick to make a thick and thin reference slide. A
venous blood sample of 3 mL was collected for the remain-
der of the tests, after which the patient’s participation in
the study was complete. Study diagnostic tests were not
used in any treatment decision; patients were treated by
the clinic doctor based on the results of the clinic slide
and/or the clinician’s judgment according to local guide-
lines. Venous blood samples were then transferred to the
Malaria Reference Centre (within two hours of collection),
where the remaining procedures were carried out.
Approximately 10 μL of venous blood was spotted on to
Whatman™ 3 MM chromatography paper (Whatman,
USA), dried and stored for later processing by PCR. A sec-
ond reference blood slide was made with venous blood and
both slides were stained with 3% Giemsa and double-read
blind to the other test results by two experienced micro-
scopists in separate locations. Capillary and venous parasite
counts were compared since the RDTs were tested on
venous blood, but capillary blood is more typically used for
both microscopy and rapid tests. Leukocyte counts were
determined for each patient and used to calculate parasite
counts per μL of whole blood in the thick film via standard
methods [35]. A slide was declared negative if neither refer-
ence microscopist observed parasites after examination of
at least 100 fields.
Finally, the six rapid tests (one stored at room tem-
perature and one stored in an EC box for each model)
were set out on a photographic panel (insert, Figure 2)
and performed in each case according to the manufac-
turer’s instructions. A plastic Pasteur pipette provided
with the CareStart tests was used to transfer 5 μL of
blood from the collection tube to the sample reception
well on each test. For all CareStart tests, 2 drops of the
relevant buffer were added to the buffer well; for the
Bioline test, 4 drops of the provided buffer were added.
Test results were read after 20 minutes. A quality con-
trol photograph was taken of each panel and later inter-
preted by one of the investigators (AFWM) who was
blind to the original results. All laboratory results and
patient data (age, sex and recruitment clinic) were
recorded on pro-formas and double-entered blind into a
Microsoft access database.
DNA extraction from filter paper blood spots
Crude DNA was extracted from filter paper blood spots as
previously described [36] but with the following minor
modifications: spots were first washed in 500 μL PCR-
grade water. The spots were then incubated at 95°C for 30
minutes in 150 μL of an extraction buffer comprising a 1:3
dilution of Tris-EDTA buffer, pH8. The crude DNA
extract was stored in a -20°C freezer until use.
Malaria confirmatory species identification PCR
PCR was performed on the crude DNA extracts as
described by Mangold et al [37], with some adaptations to
account for an alternative choice in kits and real time plat-
form. Briefly, 5 μL of the crude DNA extract was added to
12.5 μL Absolute blue 2× SYBR green mastermix (ABgene,
Surrey, UK), 5 μL nuclease free water and 2.5 μL of the
consensus primer pair at a final concentration of 0.6 mM
(Eurofins MWG Operon, Ebersberg, Germany). The reac-
tions were transferred to an ABI 7300 real time PCR sys-
tem with the following amplification programme: initial
denaturation at 95°C for 15 minutes, followed by 40 cycles
of 15 s at 94°C, 30 s at 50°C and extension for 30 s at
72°C. A dissociation curve was generated under the default
ABI 7300 conditions. Species discrimination was achieved
by determining the melting temperature peak of each sam-
ple relative to positive control peaks for P. falciparum
(77.5 +/- 0.2°C), P. vivax (81.5 +/- 0.6°C), Plasmodium
malariae (76.5 +/- 0.5°C), Plasmodium ovale curtisi (79.6
+/- 0.2°C) and Plasmodium ovale wallikeri (79.1 +/-
0.2°C). Positive control DNA for each species was pro-
vided by C. Sutherland from the Malaria Reference Centre
at the London School of Hygiene & Tropical Medicine.
Data analysis
Data was double-entered into a Microsoft Access database
and cross-checked with the Epinfo® Data Compare mod-
ule. Any discrepancies were corrected with reference to
paper record forms. The dataset was analysed with the sta-
tistical software R® (version 2.10.1) and Stata™ (version
8.2). A Wilcoxon signed-rank test was performed to deter-
mine if parasite levels in capillary and venous blood were
different, while the level of agreement between pairs of
reference results (two microscopy reads and PCR) was
determined by Kappa values.
The sensitivity, specificity and global performance index
of each RDT were determined using consensus reference
results as the gold standard. The consensus standard was
derived from both reference microscopy and PCR results
without designating any single method as superior to the
others, in a similar manner to that described by Boonma
and colleagues [38]. A positive result from at least two of
the three reference variables was scored as positive in the
consensus variable and only samples that had negative
results in all three reference variables were scored as nega-
tive. Samples for which only one reference result was posi-
tive were subjected to repeat microscopic examinations or
PCR and the result generated was used as a tie-breaker.
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As the RDTs investigated in this study were being con-
sidered for national deployment, a composite measure of
global test performance was calculated, whereby in addi-
tion to separate indicators of performance such as sensi-
tivity and specificity, the tests could also be compared
with a single score. The global performance index (GPI)
for each RDT was determined by expressing the number
of true test results (both true positive and true negative)
as a proportion of the total tested, thus incorporating
sensitivity, specificity and the invalid rate in one unit. For
the purposes of this calculation, invalid test results were
not scored as true results but were included in the
denominator (total tested). The three components were
not differentially weighted in the formula as it was con-
sidered that each measure would be of equal importance
to a national programme, albeit for different reasons.
Appropriate statistical tests of significance were used
for the main outcomes; specifically, McNemar’s statistic
was used to compare the global performance index
between tests stored in evaporative coolers and at room
temperature and Fisher’s exact test was used to deter-
mine the significance of parasite level effects on the glo-
bal performance index of the RDTs.
Ethics review
This study was approved by the Institutional Review
Board of the Ministry of Public Health, Kabul,
Afghanistan (IRB) and the ethics committee at the Lon-
don School of Hygiene and Tropical Medicine. All parti-
cipants or their guardians gave written informed consent.
The study was designed and performed in compliance
with Standards for Reporting of Diagnostic Accuracy
Studies (STARD) guidelines [39].
Results
In total, 306 patients were recruited. Of the 26 samples
with a malaria negative slide at recruitment, 21 were con-
firmed as negative, but four were later determined to be
infected with P. vivax and one with P. malariae according
to the consensus reference standard (Figure 2). Of the 280
samples with a vivax positive slide at recruitment, all were
confirmed to be infected with P. vivax. Seventeen records
were excluded from parasite level analysis due to missing
reference microscopy results. RDT results were scored as
true positive, true negative, false positive, false negative or
invalid according to the consensus gold standard (Table 1)
and these groupings were used for all subsequent
calculations.
Performance of the evaporative cooler box
The evaporative cooler was examined for its capacity to
protect tests, defined as the ability of the box to maintain
an internal temperature of less than 30°C, when the
ambient temperature is above 30°C. Initially, temperature
Figure 2 Process flow chart of study design and patient recruitment.
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differentials and relative humidity were assessed over an
eight-day period prior to the start of the study. The box
was placed in a typical un-cooled room inside the study
clinic. Ambient temperature in the room ranged from 30
to 33°C, whereas temperature inside the EC box ranged
from 20 to 26°C. Thereafter, temperature differentials in
relation to relative humidity were continuously moni-
tored during clinic hours (from eight in the morning
until two in the afternoon) for the duration of the study
(Figure 3). Temperature inside the box varied over a
wider range than ambient temperature in the room and
this was positively correlated with relative humidity (R2 =
0.8, P = < 0.0001). Despite this variation, EC box tem-
perature remained significantly lower than room tem-
perature at all times; the average temperature differential
was 8°C and ranged from 4 to 14°C. The highest ambient
temperature (37°C) was recorded mid-study on 8th July,
at which time the corresponding temperature in the EC
box was 23°C.
Quality of the reference standard
RDT results were compared with a consensus gold stan-
dard, comprising the consensus result between two refer-
ence microscopy reads and the PCR result. The quality of
each component in the gold standard was first verified by
calculating the level of concordance and resultant kappa
values for each pair of results. The two microscopy reads
for both capillary and venous blood slides demonstrated
high levels of agreement (98.98% and 98.96% respectively,
with a kappa value of 0.93 in both cases). The level of
concordance between each reference microscopy read
and PCR results were lower (97%, with a kappa value of
0.85 and 6 non-concordant results in all four cases). The
majority of non-concordant results (5/6) were from refer-
ence slides scored as negative that had a positive PCR
result and presumably had sub-microscopic parasitaemia.
The remaining sample (NHD_017) was positive for P.
vivax on all four reference slides and all 6 rapid tests, but
repeatedly Plasmodium negative by Mangold PCR. This
sample was re-tested with three alternative PCR assays
(Snounou nested PCR [40], Shokoples taqman PCR [41]
and the Sharp taqman assay for detection of P. vivax
[42]) by the malaria reference centre at the London
School of Hygiene and Tropical Medicine; all three assays
performed at the London School were also positive for P.
vivax. PCR inhibition was identified as the likely reason
for discordant results for this sample, since a crude
extraction method was employed in Kabul that may not
have been sufficient to remove all inhibitors, whereas a
more robust Chelex resin extraction technique was used
for the PCRs performed in London.
Impact of blood source on parasite levels
To minimize discomfort for the patients, a single venous
blood sample was collected from each donor and
employed to evaluate the performance of the six rapid
tests. Given that the more typical blood source for rapid
tests is capillary, both capillary and venous blood slides
were made for each patient and parasitaemia ranges
from the two sources were compared with a Wilcoxon
signed rank test. The analysis revealed a moderately sig-
nificant difference between the two blood sources in
one direction (P = 0.0059); parasitaemia levels were
slightly higher in capillary blood than venous blood.
Importantly, the venous blood used to evaluate the
RDTs also had lower minimum parasitaemia levels than
capillary blood (26 versus 175 asexual parasites/μL,
respectively).
Overall performance of RDTs
Both traditional comparative indicators for diagnostic
tests (sensitivity and, specificity) and a composite mea-
sure of performance (the global performance index)
were used in this study. With the caveat that only vivax
positive and a small number of malaria negative samples
were used, all three models of RDT demonstrated 100%
specificity (95% CI 84-100). However, sensitivity and the
global performance index differed between test models
(table 2). The CareStart Pf/Pan test had the highest sen-
sitivity (98.5%) followed by the Bioline Pf/Pv test (96.5%)
while the CareStart Pf/Pv test was the least sensitive
(91.9%).
When the rapid tests were compared by their global
performance index, the CareStart Pf/Pan RDT main-
tained its lead position (GPI 95%) followed by the Car-
eStart Pf/Pv test (GPI 91%) and the Bioline Pf/Pv test
Table 1 Numerical summary of results$
RDT type Condition True +ve True -ve False +ve False -ve Invalid
CareStart Pf/Pan Room temp 271 19 0 4 12
Cool chain 275 19 0 4 8
CareStart Pf/Pv Room temp 258 20 0 23 5
Cool chain 258 20 0 22 6
Bioline Pf/Pv Room temp 223 19 0 10 54
Cool chain 249 18 0 7 32
$ Designation by comparison with consensus gold standard, for 306 samples.
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(GPI 83%). The lower GPI of the Bioline RDT was attri-
butable to the high number of invalid test results in this
model (Figure 4).
Impact of EC box storage on the global performance
index
There were no significant differences in sensitivity
between storage conditions for any of the three RDT
models (Table 2). However, the global performance
index for the Bioline test was significantly higher (P <
0.001) in the group stored in the EC box than for those
stored at room temperature. This difference was
attributable to the invalid result rate; while Bioline tests
held under both storage conditions yielded invalid
results, EC box storage resulted in a reduced number
(31 in the EC box versus 52 at room temperature).
Most of the invalid test results were due to the poor
flow of blood along the device, which often failed to
reach the control line within the test period (Table 3,
Figure 4).
Impact of parasitaemia level on RDT performance
Previous studies on P. vivax detecting rapid tests have
shown that test lines are increasingly likely to be false
negative if parasitaemia is less than 5,000/μL or less
than 500/μL, while the WHO/FIND evaluations define
low parasitaemia as less than 200 asexual parasites per
microliter. To ascertain if low parasitaemia affected
RDT performance in the present study, all three cut-off
points (<>200/μL, <>500/μL and <>5,000/μL) were initi-
ally considered. Since the proportion of samples with
parasitaemia less than 500/μL was very small (N = 4),
samples were divided into low (<5,000/μL) and high
(>5,000/μL) parasitaemia groups for subsequent analysis.
All performance parameters (sensitivity, invalid result
rates and the global performance index) were compared
for both groups.
Performance in two of the three RDTs (CareStart Pf/
Pv and Bioline Pf/Pv) were adversely affected by low
parasitaemia. For the CareStart Pf/Pv test, the global
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Figure 3 Daytime temperature and humidity in the evaporative cooler box. This box was installed in a room at the Malaria Reference
Centre, Jalal Abad and the pre-trial data shown in this image was recorded from mid-May to early June 2009. Relative humidity outside the box
is represented by the blue shaded area; room temperature is indicated by the red line and temperature inside the box is indicated by the blue
line.
Table 2 Global performance index and sensitivity of RDTs
for P. vivax
RDT name Storage GPI$ (% [95% CI]) Sensitivity (% [95% CI])
CS Pf/Pan Overall 95.1 [92.7 - 97.5] 98.6 [97.2 - 99.9]
Room temp 94.4 [91.9 - 97.0] 98.5 [97.2 - 99.9]
EC box 95.8 [93.5 - 98.0] 98.6 [97.2 - 99.9]
CS Pf/Pv Overall 90.5 [87.2 - 93.8] 91.9 [88.9 - 95.0]
Room temp 90.5 [87.2 - 93.8] 91.7 [88.6 - 94.9]
EC box 90.5 [87.2 - 93.8] 92.1 [89.1 - 95.1]
BL Pf/Pv Overall 82.9 [78.7 - 87.1] 96.5 [94.3 - 98.7]
Room temp 78.8 [74.2 - 83.4] 95.7 [93.2 - 98.2]
EC box 86.9 [83.1 - 90.7] 97.2 [95.3 - 99.2]
$ GPI = (TN+TP/N) × 100 where TN, true negative; TP, true positive; N, total
tested.
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performance index and sensitivity were significantly
reduced when parasitaemia levels fell below 5,000/μL.
There was a 16% difference in GPI (P = < 0.0001, table
4), while sensitivity decreased from 97.5% to 82% in the
low parasitaemia group.
For the Bioline Pf/Pv test, the proportion of invalid
results increased by 10% in the EC box and 12% at
room temperature in the high parasitaemia group
(> 5,000/μL) when compared to the low parasitaemia
group (P < 0.01). The resultant differences in GPI were
smaller and non-significant because there were also a
number of false negative RDT results in the low parasi-
taemia group (5 in the EC box and 7 at room tempera-
ture, respectively) but none in the high parasitaemia
group (Table 5).
Discussion
In this study, the performance of three multiple species
combination rapid tests for malaria were evaluated in
Afghanistan against a typical sample of patients present-
ing with a representative range of different levels of
vivax parasitaemia; the results revealed clinically
important differences between RDT models. An eva-
porative cooler box was simultaneously evaluated to
determine if this appropriate technology storage device
would prevent heat-induced deterioration in test sensi-
tivity or global performance index under operational
conditions. The unit proved to have a positive impact
on some test models, while surprisingly it did not
improve sensitivity to low parasitaemia.
Evaporative cooler box performance
As P. vivax-detecting RDTs are known to be particularly
vulnerable to heat damage, their effective deployment
for national programmes is dependent on the provision
of locally appropriate cool chain storage solutions. In
this investigation, evaporative cooling technology was
selected for evaluation as it does not require electricity,
could be made locally, requires little maintenance and
could be placed anywhere in the clinic. This cooling sys-
tem is also familiar to local end users, since the same
Figure 4 Examples of invalid RDT results. Photos of invalid RDTs (A - C) and one functional RDT (D). Panel A shows error type 1 (blood did
not clear after 20 minutes); Panel B shows error type 2 (control line not reached by the sample after 20 minutes); Panel C shows error type 3
(control line did not appear after 20 minutes).
Table 3 Causes of rapid test invalidation$
Test type Storage type Type 1a
N (%)
Type 2b
N (%)
Type 3c
N (%)
CS Pf/Pan Room temp 0 2 (100) 0
EC box 0 0 0
CS Pf/Pv Room temp 0 1 (100) 0
EC box 1 (50) 1 (50) 0
BL Pf/Pv Room temp 17 (33) 23 (44) 12 (23)
EC box 13 (42) 13 (42) 5 (16)
$ Not including tests invalidated by operator error
a Type 1: Blood not cleared
b Type 2: Control line not reached
c Type 3: Control line absent
Table 4 Effect of storage condition and parasite level on
RDT global performance index
Rapid test name Storage < 5,000 T/μL > 5,000 T/μL
CareStart Pf/Pan Room temp 94.1
[89.8 - 98.4]
96.8
[94.1 - 99.6]
EC box 95.8
[92.1 - 99.5]
98.10
[96.0 - 100.0]
CareStart Pf/Pv Room temp* 81.5
[74.4 - 88.6]
98.1
[95.6 - 100.0]
EC box* 82.4
[75.4 - 89.3]
97.5
[95.0 - 99.9]
Bioline Pf/Pv Room temp 82.4
[75.4 - 89.3]
76.6
[69.9 - 83.3]
EC box 90.8
[85.5 - 96.1]
85.4
[79.9 - 91.0]
* Significant difference between false result rates for low and high
parasitaemias.
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technique is used to keep water pitchers cool during the
summer.
A preliminary objective of this evaluation was to
determine whether a locally made evaporative cooling
box could maintain an internal temperature within the
range recommended for storage of RDTs by manufac-
turers (typically between 15 and 30°C). This was rea-
lized, since throughout the study, temperature within
the box never exceeded 30°C, even though the maxi-
mum temperature recorded outside the box during the
study period was 37°C. As expected, increasing daily
temperatures did not adversely affect the ability of the
cooler to maintain significantly lower internal tempera-
tures, but increasing relative humidity did reduce the
cooling capacity of the box, resulting in smaller tem-
perature differentials. These results correspond well
with the findings of a Cambodian pilot study on eva-
porative cooler boxes of a similar design [31]. Because
on average relative humidity in Afghanistan is low and
does not exceed 70%, a higher average temperature dif-
ferential can be achieved that would work in favour of
this technology in the Afghan setting. During the study,
the maximum temperature differential achieved was 14°
C (RH 20%).
Additionally, the EC box was tested in eastern Afghani-
stan, where summer temperatures typically exceed 40°C
and are representative of the hotter, low-lying regions in
the country where most malaria transmission occurs.
Winter temperatures were not considered in this
investigation, although they could potentially cause diffi-
culties as during this season most provinces experience
sub-zero temperatures, particularly at night. Alternative
mechanisms would have to be considered to protect RDTs
from freezing during the winter months.
The principle objective was to ascertain if the evapora-
tive cooler box could mitigate or prevent heat-induced
deterioration in rapid test performance. To examine
this, all performance parameters were compared for
tests that had been stored at room temperature versus
those that had been stored in the EC box. However, the
impact of the box on test performance cannot be under-
stood without prior reference to the individual charac-
teristics of the rapid tests; a contextual overview of the
performance characteristics of each RDT is, therefore
given below.
CareStart PfPan
The CareStart PfPan test detects P. falciparum HRP2 with
falciparum-specific antibodies in the first test band and
Plasmodium species lactate dehydrogenase (LDH) with
pan-specific antibodies in the second test band. Of the
three RDTs evaluated, this test was the only device that
met and exceeded WHO standard requirements for
national deployment, irrespective of pre-use storage condi-
tions and sample parasitaemia levels (sensitivity, specificity
and global performance index were above 95%). The con-
trol line failed to appear in only two out of 612 tests, both
of which had been stored at room temperature.
The test produced one false negative result (under
both storage conditions), for a sample which was later
determined to be infected with P. malariae and had the
lowest parasitaemia of all the samples tested. The P.
malariae infection in this sample was initially detected
by Mangold PCR, as one reference read reported both
blood slides to be negative and the second misidentified
the infecting species as P. vivax. Species identification
was later verified by the corresponding author, who
located two characteristic band form trophozoites in the
thin film. Plasmodium malariae is extremely rare in the
region, but has been documented previously [43] and
may be under-reported due to the difficulties of identify-
ing this parasite with typical clinic microscopy, where
the thin film is rarely viewed [44].
As such, the very low parasitaemia level of this sample
was the most probable cause of detection failure; the
parasites were also missed by one of the reference
microscopists and the real-time PCR signal crossed the
threshold at 37 cycles, indicative of a very low concen-
tration of target DNA. Of the published evaluations on
pan-specific LDH detecting RDTs, very few have
reported on their ability to detect P. malariae; where
this has been examined, sensitivities for the parasite
range from 30 [45] to 45% [46] and in the latter case,
Table 5 Effect of parasite level on rapid test results
RDT type Rapid test results Slide results
Storage Invalid Negative Positive Parasitaemia
CS PfPan Room temp 1 22 1 Negative
6 1 112 Low a
5 0 153 High b
EC box 1 22 1 Negative
4 1 114 Low
3 0 155 High
CS PfPv Room temp 0 23 1 Negative
3 19 97 Low
2 1 155 High
EC box 0 23 1 Negative
3 18 98 Low
3 1 154 High
BL PfPv Room temp 2 22 0 Negative
14 7 98 Low
37 0 121 High
EC box 3 20 1 Negative
6 5 108 Low
23 0 135 High
a Low parasitaemia: < 5,000/μL;
b High parasitaemia: > 5,000/μL
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poor sensitivity was attributed to the low parasitaemia
levels typical of this species.
At the time of writing, there are seven published stu-
dies that have reported on the use of the CareStart Pf
(HRP2) Pan(pLDH) test to detect P. vivax. Of these, two
were field studies conducted in Uganda [16] and Mada-
gascar [34], where the number of vivax cases was insuf-
ficient to draw any conclusions about this species; a
third study consisted of a large school-based survey in
Ethiopia, where test sensitivity was not reported [47].
An additional two studies conducted in reference set-
tings reported sensitivities of 77.6% [45] and 79.2% [48];
in both cases considerably lower than that determined
in the present study. Field studies conducted in Myan-
mar [15] and Ethiopia [30] also report lower sensitivities
of this RDT to P. vivax (78.5% and 85%, respectively),
although in both cases the authors note that the CareS-
tart test was more sensitive to P. vivax than the other
RDTs they had tested in parallel.
There are a number of possible reasons for the higher
sensitivity determined in this study. One key distinction
between field and reference settings is that in the field,
the source of blood is fresh, whereas studies conducted
in reference settings typically use frozen samples, where
repeated freeze-thaw cycles may have damaged some of
the antigens resulting in artificially reduced test sensitiv-
ity. A second potential factor is antigen variability;
although LDH antigens are generally thought to be less
heterogeneous than HRP2, a small amount of variation
has been detected (see [14] for example). The samples
used in the present study were collected from a single
region in eastern Afghanistan and are therefore likely to
have low within-sample variation.
Lastly, these differences may be attributable to the dif-
ferent proportions of hypo-parasitaemic patients in each
study. For example, 28/254 samples with parasitaemia <
500/μL were evaluated with the pan-specific model in
Ethiopia, as compared to only 4/280 samples with this
level of parasitaemia in the present study. Patients with
very low parasitaemias may have been under-repre-
sented, as the main criterion for enrolment was a vivax
positive slide as determined by clinic microscopists with
varied levels of expertise. This may have reduced the
scope for recruiting a sufficient number of hypo-parasi-
taemic patients; none the less, a sensitivity of 98.6% may
be considered representative for this RDT where sample
parasitaemia is greater than 500 parasites per microliter.
CareStart PfPv
The CareStart PfPv test detects P. falciparum with falci-
parum-specific HRP2 antibodies and P. vivax with
vivax-specific antibodies to lactate dehydrogenase.
Although this test also demonstrated 100% specificity,
its global performance index was lower than the other
two RDTS, due to its reduced performance at parasite
densities below 5000/μL. Reduced sensitivity at this level
of parasitaemia is not unusual in P. vivax detecting
RDTs; field evaluations of the Standard Diagnostics
FK70 RDT and ICT malaria Pf/Pv yielded reductions in
sensitivity of 19% and 26% below 5,000/μL, respectively
[28,29]. In the present study, test sensitivity was also
markedly reduced from 98% to 82%. Sixteen samples
were scored as false negative under both storage condi-
tions, with parasite densities ranging from those unde-
tectable by microscopy (with a positive PCR result) to
3261/μL. A further seven and five RDTs, respectively,
were only false negative under one storage condition
(room temperature or evaporative cooler). There was no
discernable pattern to the results falling within this
group, which can be interpreted to mean that parasite
densities below 5,000/μL reduce the reliability and accu-
racy of this test, but do not always result in false
negatives.
At the time of writing, the CareStart Pf/Pv RDT has
been assessed in the second round of the WHO/FIND
evaluation [18] and in two published field studies, which
were carried out in Ethiopia [49], [50]. Although the
WHO/FIND evaluation was carried out in a non-opera-
tional setting, a drop in global performance index of
10% from standard (> 2000/μL) to low (< 200/μL) para-
site densities was observed, indicating that the test per-
formed better at low parasitaemia than in this
investigation. This may have been due to the more con-
trolled setting in the latter study, or the limited number
of source sample materials utilized.
Both Ethiopian field studies found the overall sensitiv-
ity to P. vivax to be higher (95.3% in Jimma and 99% in
Wondo Genet) than was found in the present investiga-
tion; however a complete breakdown of parasite densi-
ties in the study population was not reported in either
case. A small number of false negatives were identified
in Jimma, where the authors cite parasitaemia < 100/μL
as the reason for non-detection. Because this RDT
detects P. vivax specifically, it is unlikely to be used in
regions where the number of vivax cases is negligible.
Further evaluations of this test in other regions are
needed to determine if the problems identified here
remain an issue outside the current study setting. How-
ever, recent results from a multi-site randomized trial of
this device in clinics situated in the same province show
consistently reduced sensitivity at low parasite densities,
with end users reporting a perception that the test is
sometimes unreliable as compared to other methods
(Leslie et al., unpublished results).
Interestingly, storage of this test in the evaporative
cooler had no impact on sensitivity to low parasite den-
sities. A link between poor sensitivity to a low parasitae-
mia and heat damage has previously been documented
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for some RDTs [12], although there were no P. vivax
samples in the test panel, nor in the heat stability tests
conducted as part of either of the recently completed
WHO/FIND evaluations [17,18]. A literature search
yielded only a single reference to reduced sensitivity for
P. vivax low parasitaemia after heat exposure, in the
ICT Pf/Pv device [30]. The lack of information on this
interaction is partly due to the difficulty of culturing
P. vivax parasites for stability testing; it is also difficult
to obtain standardized parasite densities from wild sam-
ples. In general, though, the relationship between heat,
parasitaemia and RDT performance appears to be more
complex than previously thought - even for pan-specific
detection of P. falciparum LDH - and may only have
relevance for a limited selection of RDTs. The cause of
the reduced sensitivity to low parasitaemia for this test
remains unclear and merits further investigation.
Bioline PfPv
The Bioline PfPv test detects P. falciparum HRP2 with
the first test line and P. vivax-specific LDH with the
second test line. As with the other two devices in this
evaluation, test specificity was 100%. Of the two vivax-
specific devices, the Bioline test was more sensitive
(maintaining sensitivity above 90% under both storage
conditions and irrespective of parasite density). How-
ever, the test produced an unusually high number of
invalid results, which resulted in a global performance
index of only 82.9%.
In addition to inclusion in round 2 of the WHO/FIND
evaluations, the Bioline PfPv test has been subjected to a
single trial in a reference setting [51]. To date, no other
studies have been conducted on this test in the field.
Sensitivity to vivax parasites in the reference setting was
lower than that reported here (75.8%), with a significant
reduction in sensitivity to parasite densities < 500/μL. A
single test line, vivax-specific LDH device made by the
same company has also been evaluated in a reference
setting [52] and in Korea [28], with overall sensitivities
of 88% and 93.4%, respectively. Reduced sensitivity to
low parasitaemia is reported in both cases; however over
40% of patients recruited in Korea had parasite densities
below 500/μL, making it difficult to compare with the
higher parasite levels seen in the Afghan setting.
Although an unusually high number of invalid tests
were recorded in the present study, the phenomenon
has received scant attention elsewhere. Invalid result
rates for rapid tests may be under-reported, because the
traditional parameters used to measure the performance
of diagnostic tests (sensitivity, specificity, negative and
positive predictive values) do not take invalid results
into account. Moreover, during field trials, operators are
typically instructed to disregard invalid results and
repeat the tests; unless specific mechanisms are
instigated to record them, the data is lost. In the current
investigation, photographs of the rapid tests were taken
20 minutes after sample and buffer deposition, allowing
for easy discrimination between operator errors and test
failure, as well as facilitating characterization of the rea-
sons for an invalid result. In some cases, the blood did
not clear from the background (rendering the test result
illegible), while in others the blood sample had stopped
progressing up the strip and failed to reach the control
line. Notably, this is similar to observations for the Bio-
line single band vivax-specific LDH test in the reference
setting [52]; the authors of that study also described dif-
ficulties with the progress of both buffer solution and
sample up the strip on two occasions.
The proportion of invalid results was affected by both
parasitaemia levels and storage temperatures. Contrary
to expectations, the test performed worse at parasite
densities greater than 5,000/μL, exhibiting almost twice
the number of invalid results. The Global performance
index was lowest for tests that had been challenged with
highly parasitaemic samples and stored at room
temperature.
The maximum parasite density for an invalid result
was 28,181/μL and PCR cycle thresholds consistently
fell below 30, indicative of the high levels of parasite
DNA in these samples. A plausible explanation for this
may be that the viscosity of the blood samples increased
with increasing parasitaemia [36], thus restricting sam-
ple flow up the device and preventing the sample from
reaching the control area, causing an invalid result.
Although host-cell clumping is a phenomenon typically
associated with P. falciparum, one study has also docu-
mented both increased cell rigidity and clumping beha-
viour in erythrocytes infected with vivax parasites [53].
Both these factors would increase the viscosity of
infected blood, in proportion to parasitaemia levels.
The Bioline PfPv test was the only device assessed in
this study for which storage in the evaporative cooler
box had a notably positive effect on performance. The
invalid rate was significantly reduced when the tests
were stored in the EC box. It is possible that warmer
room temperatures may have resulted in some kind of
mechanical damage, such as warping, to the device. If
this were the case, it could explain why the flow of the
sample up the strip was either curtailed completely, or
slower than the time allotted for clearance of the test
window by the manufacturer (maximum 30 minutes).
Applicability of the study design for national
programmes
The findings of the present study were used by the
National Malaria and Leishmaniasis Control Programme
to identify a suitable RDT for country-wide implementa-
tion. Three features of the study design proved to be
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particularly suitable in assisting with the decision mak-
ing process.
Firstly, parasite positive patients were deliberately cho-
sen as the focus of this study, which resulted in a wide
and representative range of natural parasite densities.
Slide positivity rate in Nangarhar rarely exceeds 20%;
thus a much larger sample size would have been neces-
sary to recruit the equivalent number of positive cases if
all fever patients who presented at the clinics had been
enrolled. One potential draw-back of this method is that
extremely low parasite positive samples at the detection
limit of expert microscopy are less likely to be included
in the study sample. However, some RDTs did fail to
register the samples with the lowest parasitaemia in the
study as positive. In addition, three out of sixteen sam-
ples scored as negative by reference microscopy, which
were also negative by all six RDTs, had positive PCR
results.
Secondly, all RDT types and storage variants were per-
formed in parallel for each sample and a high-resolution
photograph of the panel was taken immediately after the
results were read. This mechanism proved to be invalu-
able for quality assurance of the test results. RDTs may
generate false positives if left for longer than the recom-
mended reaction time, either due to decreased specificity
of the reaction over time [54] or to the used test being
adversely affected by humidity [55], so they cannot be
stored for future independent examination. Photographic
quality control provides a permanent record from which
the types of invalid test and false positive or false negative
results can be further categorized.
Finally, the use of the global performance index as a
composite measure of test function in this study has
greatly facilitated comparisons between the selected
RDTs. Sensitivity and specificity analysis are typically
used to evaluate diagnostic tests against a gold standard.
However, these measurements can be misleading, as
invalid test results are not included in these calculations
and have to be reported separately. The number of inva-
lid tests is an important consideration for at-scale use of
these tests, because they could result in significant
resource wastage and loss of faith in the device by end
users. Thus, although the CareStart Pf/Pan test per-
formed better than the others by any of the measure-
ment criteria used, differences in sensitivity between this
test and the Bioline test are quite moderate. If sensitivity
and specificity alone were considered, it would be easy
to draw the false conclusion that the two types of RDT
have comparable performance; while in fact the Bioline
test, if the invalid rate is taken into account, scores con-
siderably lower.
Lastly, the global performance index may be a more
appropriate measure to use when, as in this case, the
proportion of true negative and true positive samples
are not equivalent. Although intra-reader and intra-lot
variation were not investigated in this study, the global
performance index could also be expanded for use in
this context, by comparing or averaging the score for
multiple readers or test lots.
Study limitations
This study was designed as a precursor to larger rando-
mized trials of malaria rapid diagnostic tests in Afghani-
stan that are currently being conducted by the authors.
Due to the short nature of this pre-study, there are a
number of limitations which should be borne in mind
when considering the implications of the results.
First, the samples that were selected for the study
were predominantly P. vivax positive. This was done to
ensure speedy recruitment that would aid in the deter-
mination of test sensitivity, as the prevalence of malaria
in the study setting is low and P. vivax is the predomi-
nant species. Since the sample only included 20 malaria
negative patients, the results cannot be used to infer the
specificity of the RDTs. This phenomenon requires
further investigation with a larger number of negative
samples and some P. falciparum positive samples.
Secondly, patient recruitment was based on slide posi-
tivity according to the seven clinic microscopists. Three
of the microscopists were expert-level and had been
involved in other studies, while the remaining four had
not been involved in a research programme before. The
resultant sample is, therefore, restricted by their collec-
tive limit of detection and may not have included very
low parasitaemic samples that were below this limit.
This may be the reason why very few P. vivax positive
samples in the study had parasitaemia less than 200/μL.
Thirdly, inter-lot variation in test performance was not
investigated in this study, since in each case a single lot
was evaluated. The points of concern raised here (poor
sensitivity of the CareStart PfPv test to low parasitaemia
and the high invalid rate of the Bioline PfPv device) may
not be a consistent issue across lots. Further investiga-
tions with different lots of the same test models are
needed to confirm if these issues are persistent.
Finally, although the evaporative cooler box performed
well in this study, it had little effect on the performance
of tests that were stored within it. This may be due to the
fact that the study was conducted in a single location,
with a small number of rapid tests (306). As such, this
limits inferences that can be made on the impact of eva-
porative cooler boxes, should they be employed at-scale,
where a greater protective effect may yet be observed.
Conclusions
The CareStart Pf/Pan RDT outperformed the other two
types of RDT evaluated on all parameters measured and
gave reliable results, irrespective of storage conditions or
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the parasitaemia level in test samples. The results show
that this RDT is appropriate for vivax-predominant
regions, although the need for further evaluation against
falciparum cases in this setting is recognized.
Conversely, the two RDTs that were affected by para-
sitaemia and/or storage conditions yielded important
information; firstly, that poor sensitivity to a low parasi-
taemia may not only be due to heat damage and sec-
ondly that the mechanical operation of rapid tests may
be adversely affected by heat.
The evaporative cooler box is an appropriate storage
device for poorly resourced heath centres and its effec-
tiveness in maintaining temperatures below the recom-
mended maximum for RDTs has been demonstrated in
this study.
Finally, this investigation has highlighted the utility of
evaluating RDTs in parallel with field-collected venous
blood samples from a mainly malaria-positive study
population, using a composite measure of performance
as the primary method of comparison. Taken together,
these measures constitute a simple model for semi-con-
trolled RDT field trials which bridge the gap between
assessments of efficacy and effectiveness and may be
usefully replicated in other countries.
Acknowledgements
We thank D. Bell (WHO) for useful advice and discussions on evaporative
coolers; From LSHTM, B. Cundhill for advice on statistical analysis; C.
Sutherland for donation of positive reference controls for PCR, M. Burke and
K. Beshir for performing quality control tests on samples with discordant
PCR results. We also thank Malaria Reference Centre staff in Jalalabad who
assisted with this study and provided laboratory space and finally the
patients who participated in this study.
The opinions expressed in this paper are solely those of the authors and do
not necessarily represent the opinions of the donors or affiliated
organizations.
This research was funded by a grant to the ACT consortium from the Bill
and Melinda Gates Foundation, distributed to the Health Protection &
Research Organization, HealthNet-TPO and MERLIN as implementing partners
by the London School of Hygiene and Tropical Medicine.
Author details
1London School of Hygiene & Tropical Medicine, London, UK. 2Health
Protection & Research Organization, Kabul, Afghanistan. 3HealthNet-TPO,
Kabul, Afghanistan. 4World Health Organization, Kabul, Afghanistan.
Authors’ contributions
AFWM conceptualized the study, designed the protocol, analysed the data
and drafted the manuscript. TJL designed the evaporative cooler box,
contributed to the study design, analysis of the results and drafting of the
manuscript. MIM helped design the study protocol, trained the field staff,
supervised the field work and contributed to analysis of the results. RZ
performed the Mangold malaria PCRs and interpreted the results. NM
contributed to the study design, facilitated and monitored the field work,
and critically reviewed the manuscript. MAH supervised the field work and
contributed to analysis of the results. NS contributed to the study design,
facilitated the execution of the study at the Malaria Reference Centre and
critically reviewed the manuscript. CJMW contributed to the study concept
and design and critically reviewed the manuscript. MR contributed to the
study concept and design, analysis and interpretation of the results and
drafting of the manuscript. All authors have read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 28 February 2011 Accepted: 22 June 2011
Published: 22 June 2011
References
1. World Health Organization: Guidelines for the treatment of malaria. WHO
Geneva;, 2 2010.
2. Whitty CJM, Chandler C, Ansah E, Leslie T, Staedke SG: Deployment of ACT
antimalarials for treatment of malaria: challenges and opportunities.
Malar J 2008, 7:S7.
3. Salwa ME, Abd EKA, Babiker A, Hayder A, Diagn MID: Malaria overdiagnosis
and burden of malaria misdiagnosis in the suburbs of central Sudan:
special emphasis on artemisinin-based combination therapy era. Diagn
Microbiol Infect Dis 2009, 64:20-26.
4. Nicastri E, Bevilacqua N, Schepisi MS, Paglia MG, Meschi S, Ame SM,
Mohamed JA, Mangi S, Fumakule R, Di Caro A: Accuracy of malaria
diagnosis by microscopy, rapid diagnostic test, and PCR methods and
evidence of antimalarial overprescription in non-severe febrile patients
in two Tanzanian hospitals. Am J Trop Med Hyg 2009, 80:712-717.
5. Hume JCC, Barnish G, Mangal T, Armázio L, Streat E, Bates I: Household
cost of malaria overdiagnosis in rural Mozambique. Malar J 2008, 7:33.
6. Chandler CIR, Jones C, Boniface G, Juma K, Reyburn H, Whitty CJM:
Guidelines and mindlines: why do clinical staff over-diagnose malaria in
Tanzania? A qualitative study. Malar J 2008, 7:53.
7. Mwanziva C, Shekalaghe S, Ndaro A, Mengerink B, Megiroo S, Mosha F,
Sauerwein R, Drakeley C, Gosling R, Bousema T: Overuse of artemisinin-
combination therapy in Mto wa Mbu (river of mosquitoes), an area
misinterpreted as high endemic for malaria. Malar J 2008, 7:232.
8. Joshi R, Colford JM Jr, Reingold AL, Kalantri S: Nonmalarial acute
undifferentiated fever in a rural hospital in central India: diagnostic
uncertainty and overtreatment with antimalarial agents. Am J Trop Med
Hyg 2008, 78:393-399.
9. Leslie TJ, Mikhail AFW, Mayan I, Hasanzai MA, Baktash H, Nader M,
Hashimi SH, Whitty CJ, Rowland M: Accuracy of malaria diagnosis and
antimalarial drug prescription at primary healthcare level in Afghanistan.
Manuscript in preparation 2011.
10. Bell D, Peeling RW: Evaluation of rapid diagnostic tests: malaria. Nat Rev
Microbiol 2006, 4:S34-S38.
11. Coleman RE, Maneechai N, Ponlawat A, Kumpitak C, Rachapaew N,
Miller RS, Sattabongkot J: Short report: Failure of the OptiMAL rapid
malaria test as a tool for the detection of asymptomatic malaria in an
area of Thailand endemic for Plasmodium falciparum and P. vivax. Am J
Trop Med Hyg 2002, 67:563-565.
12. Chiodini PL, Bowers K, Jorgensen P, Barnwell JW, Grady KK, Luchavez J,
Moody AH, Cenizal A, Bell D: The heat stability of Plasmodium lactate
dehydrogenase-based and histidine-rich protein 2-based malaria rapid
diagnostic tests. Trans R Soc Trop Med Hyg 2007, 101:331-337.
13. Jorgensen P, Chanthap LON, Rebueno A, Tsuyuoka R, Bell D: Malaria rapid
diagnostic tests in tropical climates: the need for a cool chain. Am J Trop
Med Hyg 2006, 74:750-754.
14. Mariette N, Barnadas C, Bouchier C, Tichit M, Ménard D: Country-wide
assessment of the genetic polymorphism in Plasmodium falciparum and
Plasmodium vivax antigens detected with rapid diagnostic tests for
malaria. Malar J 2008, 7:219.
15. Ashley EA, Touabi M, Ahrer M, Hutagalung R, Htun K, Luchavez J, Dureza C,
Proux S, Leimanis M, Lwin MM: Evaluation of three parasite lactate
dehydrogenase-based rapid diagnostic tests for the diagnosis of
falciparum and vivax malaria. Malar J 2009, 8:241.
16. Fogg C, Twesigye R, Batwala V, Piola P, Nabasumba C, Kiguli J, Mutebi F,
Hook C, Guillerm M, Moody A: Assessment of three new parasite lactate
dehydrogenase (pan-pLDH) tests for diagnosis of uncomplicated
malaria. Trans R Soc Trop Med Hyg 2008, 102:25-31.
17. Malaria rapid diagnostic test performance - results of WHO product
testing of malaria RDTs: round 1 (2008). [http://www.finddiagnostics.org/
resource-centre/reports_brochures/malaria-diagnostics-report-2009.html].
18. Malaria rapid diagnostic test performance - results of WHO product
testing of malaria RDTs: round 2 (2009). [http://www.who.int/malaria/
publications/atoz/9789241599467/en/index.html].
Mikhail et al. Malaria Journal 2011, 10:169
http://www.malariajournal.com/content/10/1/169
Page 14 of 15
19. Kolaczinski K, Durrani N, Rahim S, Rowland M: Sulfadoxine-pyrimethamine
plus artesunate compared with chloroquine for the treatment of vivax
malaria in areas co-endemic for Plasmodium falciparum and P. vivax: a
randomised non-inferiority trial in eastern Afghanistan. Trans R Soc Trop
Med Hyg 2007, 101:1081-1087.
20. Nadjm B, Amos B, Mtove G, Ostermann J, Chonya S, Wangai H, Kimera J,
Msuya W, Mtei F, Dekker D, Malahiyo R, Olomi R, Crump JA, Whitty CJM,
Reyburn H: WHO guidelines for antimicrobial treatment in children
admitted to hospital in an area of intense Plasmodium falciparum
transmission: prospective study. BMJ 2010, 340.
21. Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, Anstey NM: Vivax Malaria:
Neglected and Not Benign. Am J Trop Med Hyg 2007, 77:79-87.
22. Tjitra E, Anstey NM, Sugiarto P, Warikar N, Kenangalem E, Karyana M,
Lampah DA, Price RN: Multidrug-Resistant Plasmodium vivax Associated
with Severe and Fatal Malaria: A Prospective Study in Papua, Indonesia.
PLoS Medicine 2008, 5.
23. Genton B, D’Acremont V, Rare L, Baea K, Reeder JC, Alpers MP, Müller I:
Plasmodium vivax and Mixed Infections Are Associated with Severe
Malaria in Children: A Prospective Cohort Study from Papua New
Guinea. PLoS Medicine 2008, 5.
24. Feachem RGA, Phillips AA, Targett GA, eds: Shrinking the malaria map: a
prospectus on malaria elimination. Global Health Sciences, University of
California, San Francisco; 2009.
25. Guerra CA, Howes RE, Patil AP, Gething PW, Van Boeckel TP, Temperley WH,
Kabaria CW, Tatem AJ, Manh BH, Elyazar IRF, Baird JK, Snow RW, Hay SI: The
international limits and population at risk of Plasmodium vivax
transmission in 2009. PLoS Negl Trop Dis 2010, 4:e774.
26. Brooker S, Leslie T, Kolaczinski K, Mohsen E, Mehboob N, Saleheen S,
Khudonazarov J, Freeman T, Clements A, Rowland M: Spatial epidemiology
of Plasmodium vivax, Afghanistan. Emerging Infect Dis 2006, 12:1600-1602.
27. Rowland M, Webster J, Saleh P, Chandramohan D, Freeman T, Pearcy B,
Durrani N, Rab A, Mohammed N: Prevention of malaria in Afghanistan
through social marketing of insecticide treated nets: evaluation of
coverage and effectiveness by cross sectional surveys and passive
surveillance. Trop Med Int Health 2002, 7:813-822.
28. Kim SH, Nam MH, Roh KH, Park HC, Nam DH, Park GH, Han ET, Klein TA,
Lim CS: Evaluation of a rapid diagnostic test specific for Plasmodium
vivax. Trop Med Int Health 2008, 13:1495-1500.
29. Fernando SD, Karunaweera ND, Fernando WP: Evaluation of a rapid whole
blood immunochromatographic assay for the diagnosis of Plasmodium
falciparum and Plasmodium vivax malaria. Ceylon Med J 2004, 49:7-11.
30. Ashton RA, Kefyalew T, Tesfaye G, Counihan H, Yadeta D, Cundill B,
Reithinger R, Kolaczinski JH: Performance of three multi-species rapid
diagnostic tests for diagnosis of Plasmodium falciparum and Plasmodium
vivax malaria in Oromia Regional State, Ethiopia. Malar J 2010, 9:297.
31. Chanthap L, Ariey F, Socheat D, Tsuyuoka R, Bell D: Low-technology
cooling box for storage of malaria RDTs and other medical supplies in
remote areas. Malar J 2010, 9:31.
32. Ihaka R, Gentleman R: R: A language for data analysis and graphics. J
Comp Graph Stat 1996, 5:299-314.
33. Leslie T, Mayan MI, Hasan MA, Safi MH, Klinkenberg E, Whitty CJM,
Rowland M: Sulfadoxine-pyrimethamine, chlorproguanil-dapsone, or
chloroquine for the treatment of Plasmodium vivax malaria in
Afghanistan and Pakistan: a randomized controlled trial. JAMA 2007,
297:2201-2209.
34. Ratsimbasoa A, Randriamanantena A, Raherinjafy R, Rasoarilalao N,
Menard D: Which malaria rapid test for Madagascar? Field and
laboratory evaluation of three tests and expert microscopy of samples
from suspected malaria patients in Madagascar. Am J Trop Med Hyg 2007,
76:481-485.
35. World Health Organization: Routine examination of blood films for
malaria parasites. In Basic malaria microscopy, part I: Learner’s guide. Volume
I.. 2001 edition. Geneva: WHO; 1991:65-68.
36. Bereczky S, Martensson A, Gil JP, Farnert A: Short report: rapid DNA
extraction from archive blood spots on filter paper for genotyping of
Plasmodium falciparum. Am J Trop Med Hyg 2005, 72:249-251.
37. Mangold KA, Manson RU, Koay ESC, Stephens L, Regner MA, Thomson RB
Jr, Peterson LR, Kaul KL: Real-time PCR for detection and identification of
Plasmodium spp. J Clin Microbiol 2005, 43:2435-2440.
38. Boonma P, Christensen P, Suwanarusk R, Price R, Russell B: Comparison of
three molecular methods for the detection and speciation of
Plasmodium vivax and Plasmodium falciparum. Malar J 2007, 6:124.
39. Meyer GJ: Guidelines for reporting information in studies of diagnostic
test accuracy: the STARD initiative. J Person Assess 2003, 81:191-193.
40. Snounou G, Viriyakosol S, Zhu XP, Jarra W, Pinheiro L, Rosario VE,
Thaithong S, Brown KN: High sensitivity of detection of human malaria
parasites by the use of nested polymerase chain reaction. Mol Biochem
Parasitol 1993, 61:315-320.
41. Shokoples SE, Ndao M, Kowalewska-Grochowska K, Yanow SK: Multiplexed
real-time PCR assay for discrimination of Plasmodium species with
improved sensitivity for mixed infections. J Clin Microbiol 2009,
47:975-980.
42. Sharp SC: Expression of the ‘var’ and ‘stevor’ multigene families in
Plasmodium falciparum gametocytes. London: University of London; 2006.
43. Rao TR: Malaria control using indoor residual sprays in the Eastern
province of Afghanistan. Bull WHO 1951, 3:639-661.
44. Kawamoto F, Liu Q, Ferreira MU, Tantular IS: How Prevalant are
Plasmodium ovale and P. malariae in East Asia? Parasitol Today 1999,
15:422-426.
45. Maltha J, Gillet P, Bottieau E, Cnops L, van Esbroeck M, Jacobs J: Evaluation
of a rapid diagnostic test (CareStartTM Malaria HRP-2/pLDH(Pf/pan)
Combo Test) for the diagnosis of malaria in a reference setting. Malar J
2010, 9:171.
46. Van der Palen M, Gillet P, Bottieau E, Cnops L, Van Esbroeck M, Jacobs J:
Test characteristics of two rapid antigen detection tests (SD FK 50 and
SD FK 60) for the diagnosis of malaria in returned travellers. Malar J
2009, 8:90.
47. Ashton RA, Kefyalew T, Tesfaye G, Pullan RL, Yadeta D, Reithinger R,
Kolaczinski JH, Brooker S: School-based surveys of malaria in Oromia
Regional State, Ethiopia: a rapid survey method for malaria in low
transmission settings. Malar J 2011, 10:25.
48. Khairnar K, Martin D, Lau R, Ralevski F, Pillai DR: Multiplex real-time
quantitative PCR, microscopy and rapid diagnostic immuno-
chromatographic tests for the detection of Plasmodium spp:
performance, limit of detection analysis and quality assurance. Malar J
2009, 8:284.
49. Mekonnen Z, Ali S, Belay G, Suleman S, Chatterjee S: Evaluation of the
performance of CareStart Malaria Pf/Pv Combo rapid diagnostic test for
the diagnosis of malaria in Jimma, southwestern Ethiopia. Acta Trop
2010, 113:285-288.
50. Sharew B, Legesse M, Animut A, Jima D, Medhin G, Erko B: Evaluation of
the performance of CareStart Malaria Pf/Pv Combo and Paracheck Pf®
tests for the diagnosis of malaria in Wondo Genet, southern Ethiopia.
Acta Trop 2009, 111:321-324.
51. Gillet P, Van Dijk DPJ, Bottieau E, Cnops L, Van Esbroeck M, Jacobs J: Test
characteristics of the SD FK 80 Plasmodium falciparum/Plasmodium vivax
malaria rapid diagnostic test in a non-endemic setting. Malar J 2009,
8:262.
52. Gillet P, Bosselaers K, Cnops L, Bottieau E, Van Esbroeck M, Jacobs J:
Evaluation of the SD FK 70 Malaria Ag Plasmodium vivax rapid
diagnostic test in a non-endemic setting. Malar J 2009, 8:129.
53. Jayavanth S, Singh M: Influence of malaria parasite (P. vivax) on
erythrocyte aggregation: a study based on dynamic imaging and
analysis. Indian J Exp Biol 2004, 42:955-963.
54. Maltha J, Gillet P, Cnops L, van den Ende J, van Esbroeck M, Jacobs J:
Malaria rapid diagnostic tests: Plasmodium falciparum infections with
high parasite densities may generate false positive Plasmodium vivax
pLDH lines. Malar J 2010, 9:198.
55. Gillet P, Mori M, Van den Ende J, Jacobs J: Buffer substitution in malaria
rapid diagnostic tests causes false-positive results. Malar J 2010, 9:215.
doi:10.1186/1475-2875-10-169
Cite this article as: Mikhail et al.: Field trial of three different
Plasmodium vivax-detecting rapid diagnostic tests with and without
evaporative cool box storage in Afghanistan. Malaria Journal 2011
10:169.
Mikhail et al. Malaria Journal 2011, 10:169
http://www.malariajournal.com/content/10/1/169
Page 15 of 15
